The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
Though broad questions intensify, NTLA-2001 continues showing clinically what it is meant to.
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Like its two competitors Precision shows lack of durability with its allogeneic Car-T approach, but makes a quick move to next-gen assets.
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.